Current Edition

ALS

Gene therapy developer gets chance at a comeback with Pfizer deal

Voyager’s first generation of gene therapies for ALS, Parkinson’s and Huntington’s disease, all now discontinued, relied on a direct infusion into brain tissue, an invasive …

Continue Reading →